Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Research & Development (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Research & Development for 11 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 30.04% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.3 million through Dec 2025, up 5.22% year-over-year, with the annual reading at $6.3 million for FY2025, 5.22% up from the prior year.
  • Research & Development for Q4 2025 was $1.7 million at Niagen Bioscience, down from $1.8 million in the prior quarter.
  • The five-year high for Research & Development was $2.1 million in Q1 2024, with the low at $787000.0 in Q1 2021.
  • Average Research & Development over 5 years is $1.3 million, with a median of $1.3 million recorded in 2022.
  • The sharpest move saw Research & Development surged 75.61% in 2024, then crashed 39.95% in 2025.
  • Over 5 years, Research & Development stood at $1.0 million in 2021, then grew by 22.39% to $1.3 million in 2022, then fell by 9.38% to $1.2 million in 2023, then increased by 13.46% to $1.3 million in 2024, then soared by 30.04% to $1.7 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $1.7 million, $1.8 million, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.